Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835807 | 0.85 | FYN (0.45) | TDO2MAP4K1MAP4K4DGAT1SOAT1 | |
| SCHEMBL2337627 | 0.74 | CNR2 (0.47) | CNR2TDO2MAP4K1 | |
| SCHEMBL836435 | 0.74 | CNR2 (0.47) | CNR2TDO2MAP4K4 | |
| SCHEMBL2337615 | 0.74 | CNR2 (0.45) | CNR2TDO2ERN1MAP4K1 | |
| SCHEMBL1055595 | 0.73 | ALOX15 (0.51) | CNR2AKR1C3 | |
| SCHEMBL16773016 | 0.71 | CNR2 (0.69) | CNR2DGAT1SOAT1KCNH2 | |
| SCHEMBL13354353 | 0.70 | CYP11B2 (0.63) | CNR2CYP11B2ERN1MAP4K1KCNH2 | |
| SCHEMBL1691904 | 0.70 | FLT3 (0.41) | — | |
| SCHEMBL7294070 | 0.70 | CNR2 (0.62) | CNR2MAP4K4KCNH2 | |
| SCHEMBL12864090 | 0.70 | CNR2 (0.62) | CNR2CYP11B2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2183027-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2183027-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204235-A1 | ORGANIC COMPOUNDS | ALK, OR10J3, FFAR4 | CNR2 321/4885TDO2 3322/4885CYP11B2 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.